VISCHER advised CITIC on all Swiss law matters. The team was led by Benedict F. Christ (partner, corporate/M&A - pictured) and included Lukas Zuest (counsel, head China Desk, corporate/M&A), Aleksandra Simic (
Tags :Vischer
VISCHER advised MCAM as lead counsel. The team was led by partner Felix W. Egli (Corporate/M&A - pictured) and included partner Christoph Niederer (Tax), managing associate Thomas Steiner-Krizaj (Corporate/M&A) , counsel Peter
The team consists of Christian Wyss (Partner, Corporate / M&A), Sebastian Flückiger (Associate, Corporate / M&A), and Adrian Briner (Associate, Tax).
The VISCHER team, led by partner Adrian Dörig (Corporate Finance - pictured) included Peter Kühn (Counsel, Corporate / M & A), Moritz Jäggy (Managing Associate, Corporate / M&A), Florian Angstmann (Associate, Corporate / M&A),
The VISCHER team, led by partner Robert Bernet (Corporate / M & A - pictured) includes Peter Kühn (Counsel, Corporate / M & A), Florian Kambor (Junior Associate, Corporate / M & A) and Christian Wyss (Partner, IP).
VISCHER advised exceet Card Group on all legal aspects of this transaction. The team was led by Gian-Andrea Caprez (Partner, Corporate/M&A - pictured left) and included Flavio Langenegger (Associate, Corporate/M&A), Michel
Raphael has extensive experience in the fields of litigation and dispute resolution and has been a valuable member of the VISCHER team since 2011.
VISCHER has been advising credentis since 2010 in all financing rounds and strategic partnerships and assisted credentis and its shareholders also in this sale concluding a decade long collaboration. The team was led by Matthias Staehelin (
The team is led by Matthias Staehelin (pictured) with Vincent Reardon and Luljeta Morina (all Corporate). As previously reported by Legalcommunity.ch, Lenz & Staehelin advised Keri Medical in this transaction
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included